BioNTech's mRNA cancer therapy fails primary endpoint in head and neck trial
BioNTech announced its investigational mRNA cancer treatment did not meet the primary endpoint in a late-stage trial for head and neck cancer, marking a setback for the company's oncology pipeline.
·2 sources
